Novavax Statistics

Total Valuation

Novavax has a market cap or net worth of MXN 27.51 billion. The enterprise value is 13.97 billion.

Market Cap	27.51B
Enterprise Value	13.97B

Important Dates

The last earnings date was Friday, February 28, 2025.

Earnings Date	Feb 28, 2025
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	n/a
Shares Outstanding	n/a
Shares Change (YoY)	+51.03%
Shares Change (QoQ)	+0.12%
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	135.74M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
PB Ratio	n/a
P/TBV Ratio	n/a
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-3.57
EV / Sales	1.00
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-6.68

Financial Position

The company has a current ratio of 0.98

Current Ratio	0.98
Quick Ratio	0.89
Debt / Equity	n/a
Debt / EBITDA	n/a
Debt / FCF	-2.63
Interest Coverage	-11.55

Financial Efficiency

Return on Equity (ROE)	n/a
Return on Assets (ROA)	-8.63%
Return on Invested Capital (ROIC)	n/a
Return on Capital Employed (ROCE)	-57.13%
Revenue Per Employee	14.93M
Profits Per Employee	-4.10M
Employee Count	1,543
Asset Turnover	0.41
Inventory Turnover	22.58

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +65.33% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	+65.33%
50-Day Moving Average	175.50
200-Day Moving Average	218.24
Relative Strength Index (RSI)	51.98
Average Volume (20 Days)	897

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	8.33

Income Statement

In the last 12 months, Novavax had revenue of MXN 14.21 billion and -3.91 billion in losses. Loss per share was -25.67.

Revenue	14.21B
Gross Profit	2.34B
Operating Income	-4.83B
Pretax Income	-3.68B
Net Income	-3.91B
EBITDA	-3.82B
EBIT	-4.83B
Loss Per Share	-25.67

Full Income Statement

Balance Sheet

The company has 19.24 billion in cash and 5.49 billion in debt, giving a net cash position of 13.75 billion.

Cash & Cash Equivalents	19.24B
Total Debt	5.49B
Net Cash	13.75B
Net Cash Per Share	n/a
Equity (Book Value)	-13.00B
Book Value Per Share	-81.03
Working Capital	-530.81M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -1.82 billion and capital expenditures -272.07 million, giving a free cash flow of -2.09 billion.

Operating Cash Flow	-1.82B
Capital Expenditures	-272.07M
Free Cash Flow	-2.09B
FCF Per Share	n/a

Full Cash Flow Statement

Margins

Gross margin is 16.49%, with operating and profit margins of -34.00% and -27.49%.

Gross Margin	16.49%
Operating Margin	-34.00%
Pretax Margin	-25.89%
Profit Margin	-27.49%
EBITDA Margin	-26.89%
EBIT Margin	-34.00%
FCF Margin	n/a

Dividends & Yields

Novavax does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-51.03%
Shareholder Yield	-51.03%
Earnings Yield	-14.20%
FCF Yield	-7.60%

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Novavax has an Altman Z-Score of -4.19. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-4.19
Piotroski F-Score	n/a